Last week, we published a report in which we propose ideas on the theme of sustainable sovereignty. Technip Energies signed an agreement to acquire the Advanced Materials & Catalysts business of Ecovyst Inc, a global leader in specialty catalysts and advanced materials. The IEA is expected to reintroduce its slow transition scenario, ‘Current Policies’, in its next World Energy Outlook, probably under pressure from the Trump administration. German Chancellor Merz has hinted at a slowdown in the ...
La semaine passée, nous avons publié une étude où nous proposons des idées pour la thématique de la souveraineté durable. Technip a signé un accord en vue d'acquérir l'activité Advanced Materials & Catalysts d'Ecovyst Inc, leader mondial des catalyseurs spéciaux et des matériaux avancés. L'AIE devrait réintroduire son scénario de transition lente « Current Policies » dans son prochain World Energy Outlook, probablement sous la pression de l'administration Trump. Le chancelier allemand Merz a lai...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), September 9, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total...
dsm-firmenich achieves target of 100% purchased renewable electricity Press Release dsm-firmenich achieves target of 100% purchased renewable electricity Kaiseraugst (Switzerland), Maastricht (Netherlands), September 3, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, today announces that it has achieved its 2025 goal of sourcing 100% of purchased electricity from renewable sources, several months ahead of target. This marks a milestone in the company’s strategy to reach net-zero greenhouse gas (GHG) emissions across its operations and value chain by 2045, as validated ...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), September 2, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total...
UCB is our highest conviction BUY despite the imminent HS Phase 3 readout from MoonLake. We show the NPV downside is likely MSD, that ~40% of Bim sales are unaffected by sonelokimab & that UCB will out-muscle MoonLake across many domains. Our analysis of the HS data shows that background antibiotic use will need to be considered & that the drugs look very similar. However, UCB’s ~$5bn rebate wall, the >€1bn higher M&S spend than Moonlake & the L-T safety data all protect Bim’, as will the psoria...
Upcoming phase 3 data from Bimzelx competitor, sonelokimab (IL17A/F nanobody), in HS is expected in September. In this note, we preview the readout and outline a few potential scenarios, highlighting the potential upside/downside for UCB's stock. While the stock may take a hit if sonelokimab shows a numerical difference on the primary endpoint, this will depend on the extent of the delta, and we see more limited downside if the numerical difference is on the smaller end, particularly in the cont...
dsm-firmenich strengthens its Executive Committee for future growth as a consumer-focused company Press Release dsm-firmenich strengthens its Executive Committee for future growth as a consumer-focused company Kaiseraugst (Switzerland), Maastricht (Netherlands), September 1, 2025 dsm-firmenich is entering a new chapter, accelerating its transformation into a fully consumer-focused company, and strengthening its position as a leading creation and innovation partner in nutrition, health, and beauty. dsm-firmenich is uniquely positioned to contribute to progress with the rise of holistic w...
A director at UCB SA bought 143 shares at 199.570EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
UCB will present 26 abstracts from its epilepsy portfolio at the International Epilepsy Congress (IEC) in Lisbon, being held 30 August – 3 September. As well as qualitative and caregiver studies, the presentations will include a combined open label extension study of 412 DS and LGS patients who took part in Fintepla (fenfluramine) studies, and shows no new or unexpected safety signals with long-term sustained benefit, which we view as supportive of Fintepla's benefit in this patient population. ...
CFE: 1H results a bit light, FY outlook maintained. CMB.TECH: VLCC reasonable, pressure on Dry Bulk rates. dsm-firmenich: Givaudan CMD; Strategy 2030. Gimv: Investing in specialised healthcare services in the Netherlands. IBA: More sales but at lower margin
We reiterate our BUY rating on UCB and increase our target price from €220 to €238 following UCB's material beat in 1H25, especially driven by a strong performance of Bimzelx. We continue to see this drug as a game changer for the company, as we now model risk-adjusted peak sales of €7.8bn by 2033F. Bimzelx, alongside a continued increase in profit contribution from Evenity, should drive a Core EPS CAGR of c.+40/27% over 2024-27/30F, well ahead of its peers at +5.5% over 2024-27F. Next to this, ...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), August 26, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.